Lansdowne Partners UK LLP Purchases Shares of 14,106,660 PureTech Health PLC Sponsored ADR $PRTC

Lansdowne Partners UK LLP purchased a new stake in PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 14,106,660 shares of the company’s stock, valued at approximately $260,973,000. PureTech Health comprises 17.1% of Lansdowne Partners UK LLP’s investment portfolio, making the stock its 2nd biggest holding. Lansdowne Partners UK LLP owned about 0.58% of PureTech Health as of its most recent filing with the Securities & Exchange Commission.

Separately, Diadema Partners LP acquired a new position in shares of PureTech Health during the 2nd quarter worth about $126,000. 0.04% of the stock is currently owned by institutional investors.

PureTech Health Stock Down 0.6%

Shares of PRTC stock opened at $16.55 on Tuesday. PureTech Health PLC Sponsored ADR has a 1 year low of $13.30 and a 1 year high of $20.00. The firm’s fifty day simple moving average is $17.93 and its 200 day simple moving average is $17.33.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d)” rating on shares of PureTech Health in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has a consensus rating of “Sell”.

PureTech Health Company Profile

PureTech Health (NASDAQ: PRTC) is a clinical-stage biotherapeutics company focused on creating and developing first-in-class medicines across immunology, inflammation, oncology and neuroscience. The company operates through a model of incubating programs in-house and advancing selected assets into independent, value-creating entities. Its internal pipeline includes multiple clinical and preclinical candidates addressing fibrotic diseases, solid tumors and rare genetic disorders.

PureTech’s proprietary platform technologies span modalities such as monoclonal antibodies, small molecules and cell-based therapies.